OPKO Health, Inc.’s (OPK) company, ModeX Therapeutics Inc., announced the dosing of the first participant in the Phase I study (NCT06655324) of an Epstein-Barr virus (EBV) vaccine candidate yesterday. The EBV vaccine is being developed in collaboration with Merck, which is known as MSD outside the United States and Canada.Per management, the first participant has been dosed with novel investigational EBV vaccine targeting multiple viral proteins in the Phase I study.It is worth mentioning that this developm ...

Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosisThere are no current treatments or vaccines for EBVFirst participant dosed with novel investigational EBV vaccine targeting multiple viral proteins in Phase I study WESTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), announces dosing of the first participant in the Phase I study (NCT06655324) of an EBV vaccine candidate bein ...

Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosisThere are no current treatments or vaccines for EBVFirst participant dosed with novel investigational EBV vaccine targeting multiple viral proteins in Phase I study WESTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), announces dosing of the first participant in the Phase I study (NCT06655324) of an EBV vaccine candidate being ...

OPKO Health, Inc. (OPK) delivered an earnings per share (EPS) of 3 cents in the third quarter of 2024 against the year-ago period’s loss of 11 cents per share and the Zacks Consensus Estimate of a loss of 10 cents per share.OPK’s Revenues in DetailOPKO Health registered revenues of $173.6 million in the third quarter, down 2.8% year over year. The figure missed the Zacks Consensus Estimate by 4.3%.Lower revenues from products and services dragged the overall top line.Shares of this company gained nearly 4.1 ...

For the quarter ended September 2024, OPKO Health (OPK) reported revenue of $173.6 million, down 2.8% over the same period last year. EPS came in at $0.03, compared to -$0.11 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $181.32 million, representing a surprise of -4.26%. The company delivered an EPS surprise of +130.00%, with the consensus EPS estimate being -$0.10.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wal ...

OPKO Health, Inc. (NASDAQ:OPK) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisor, IR Phillip Frost - Chairman and CEO Elias Zerhouni - Vice Chairman, President Adam Logal - CFO Conference Call Participants Maury Raycroft - Jefferies Yi Chen - H.C. Wainwright Edward Tenthoff - Piper Sandler Michael Petusky - Barrington Research Operator Good day, and welcome to the OPKO Health Third Quarter of 2024 Financial Results Conference Call. All partici ...

OPKO Health, Inc. (NASDAQ:OPK) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisor, IR Phillip Frost - Chairman and CEO Elias Zerhouni - Vice Chairman, President Adam Logal - CFO Conference Call Participants Maury Raycroft - Jefferies Yi Chen - H.C. Wainwright Edward Tenthoff - Piper Sandler Michael Petusky - Barrington Research Operator Good day, and welcome to the OPKO Health Third Quarter of 2024 Financial Results Conference Call. All partici ...

OPKO Health (OPK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 130%. A quarter ago, it was expected that this holding company with investments in pharmaceutical and diagnostics companies would post a loss of $0.09 per share when it actually produced a loss of $0.01, deliverin ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered pursuant to Section 12(b) of the Act: | --- | --- | |---------------------------------------------------------------------------|------------------- ...

Exhibit 99.1 OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (November 7, 2024) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the third quarter of 2024 and recent weeks include the following: ● Completed sale of select assets of BioReference Health to Labcorp for $237.5 million. OPKO completed the sale of B ...